Valproate in the treatment of epilepsy in people with intellectual disability

By: Friis, M L.
Series: Journal of Intellectual Disability Research 42 supplement 1 1998: 32-35. 1998Content type: text Media type: unmediated Carrier type: volume Subject(s): DRUG THERAPY | EFFECTS | EPILEPSY | LENNOX GASTAUT SYNDROME | WEST SYNDROMESummary: Valproate is a major broad spectrum antiepileptic drug effective against many different types of epileptic seizures. Valproate is a first-line drug in the treatment of primary generalised seizures and syndromes. But it is also effective in other seizure and epilepsy types. The possible mechanisims of action and the pharmacokinetics of valproate are outlined. A limited number of studies on the efficacy and safety of valproate treatment in patients with west syndrome and Lennox-Gastaut syndrome have shown that even therapy-resistant people with intellectual disability can benefit from add-on valproate medication. In status epilepticus, valproate can be effective either intravenously by gastric drip or following rectal administration. Patient tolerance towards valproate is generally good. The most serious adverse effect of valproate include hepatotoxicity and teratogenicity.[AJ]
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Call number Status Date due Barcode Item holds
Article Research IHC Library Article (Browse shelf(Opens below)) Available (Article available on request) 10797
Total holds: 0

Valproate is a major broad spectrum antiepileptic drug effective against many different types of epileptic seizures. Valproate is a first-line drug in the treatment of primary generalised seizures and syndromes. But it is also effective in other seizure and epilepsy types. The possible mechanisims of action and the pharmacokinetics of valproate are outlined. A limited number of studies on the efficacy and safety of valproate treatment in patients with west syndrome and Lennox-Gastaut syndrome have shown that even therapy-resistant people with intellectual disability can benefit from add-on valproate medication. In status epilepticus, valproate can be effective either intravenously by gastric drip or following rectal administration. Patient tolerance towards valproate is generally good. The most serious adverse effect of valproate include hepatotoxicity and teratogenicity.[AJ]

There are no comments on this title.

to post a comment.

Powered by Koha